473 related articles for article (PubMed ID: 33729874)
1. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S
Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874
[TBL] [Abstract][Full Text] [Related]
2. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Juurlink DN
CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
[No Abstract] [Full Text] [Related]
3. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
[TBL] [Abstract][Full Text] [Related]
4. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Pani A; Lauriola M; Romandini A; Scaglione F
Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189
[TBL] [Abstract][Full Text] [Related]
5. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
Mégarbane B; Scherrmann JM
J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
[No Abstract] [Full Text] [Related]
7. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
Li C; Cheng G
Front Immunol; 2020; 11():1969. PubMed ID: 32849658
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Cavalcanti AB; Zampieri FG; Rosa RG; Azevedo LCP; Veiga VC; Avezum A; Damiani LP; Marcadenti A; Kawano-Dourado L; Lisboa T; Junqueira DLM; de Barros E Silva PGM; Tramujas L; Abreu-Silva EO; Laranjeira LN; Soares AT; Echenique LS; Pereira AJ; Freitas FGR; Gebara OCE; Dantas VCS; Furtado RHM; Milan EP; Golin NA; Cardoso FF; Maia IS; Hoffmann Filho CR; Kormann APM; Amazonas RB; Bocchi de Oliveira MF; Serpa-Neto A; Falavigna M; Lopes RD; Machado FR; Berwanger O;
N Engl J Med; 2020 Nov; 383(21):2041-2052. PubMed ID: 32706953
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
Gautret P; Honoré S; Lagier JC; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106236. PubMed ID: 33408025
[No Abstract] [Full Text] [Related]
10. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
García-Fernández A; Ramos-Ruiz P; Ibáñez-Criado A; Moreno-Pérez Ó; Cambra-Poveda C; Martínez-Martínez JG;
Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):108-111. PubMed ID: 33077410
[No Abstract] [Full Text] [Related]
11. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB;
Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292
[TBL] [Abstract][Full Text] [Related]
12. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Machiels JD; Bleeker-Rovers CP; Ter Heine R; Rahamat-Langendoen J; de Mast Q; Ten Oever J; Bousema T; van Crevel R; Wertheim HF
Int J Antimicrob Agents; 2020 Jul; 56(1):106056. PubMed ID: 32674929
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
[No Abstract] [Full Text] [Related]
14. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
Cochin M; Touret F; Driouich JS; Moureau G; Petit PR; Laprie C; Solas C; de Lamballerie X; Nougairède A
Antiviral Res; 2022 Jan; 197():105212. PubMed ID: 34838583
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
Jordaan P; Dumotier B; Traebert M; Miller PE; Ghetti A; Urban L; Abi-Gerges N
Toxicol Sci; 2021 Apr; 180(2):356-368. PubMed ID: 33483756
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
Szendrey M; Guo J; Li W; Yang T; Zhang S
J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391
[TBL] [Abstract][Full Text] [Related]
17. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
Nicol MR; Joshi A; Rizk ML; Sabato PE; Savic RM; Wesche D; Zheng JH; Cook J
Clin Pharmacol Ther; 2020 Dec; 108(6):1135-1149. PubMed ID: 32687630
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
Damle B; Vourvahis M; Wang E; Leaney J; Corrigan B
Clin Pharmacol Ther; 2020 Aug; 108(2):201-211. PubMed ID: 32302411
[TBL] [Abstract][Full Text] [Related]
20. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
